Researchers at Washington University School of Medicine in St. Louis have identified a previously unrecognized network of lymph-node-like immune structures inside the bone marrow of the skull, describing them as a kind of hidden "immune organ" that can mount a defense against brain tumors faster than the body's distant lymph nodes. The findings were published in Nature this month.
Using mice, the team traced how proteins and immune signals travel directly from the brain through small channels into the surrounding skull bone marrow, where they encountered dense clusters of immune cells organized much like lymph nodes. When the researchers deliberately disrupted these hubs, tumors in a glioblastoma model grew measurably faster and the animals survived for a shorter time than mice with intact hubs. The team also found evidence of similar immune-cell clusters in samples of human skull bone marrow, suggesting the structures are not unique to mice.
Why it matters
The brain has long been considered relatively cut off from the body's immune system, protected by the blood-brain barrier and reliant on lymph nodes in the neck to mount slower, delayed responses. The new structures appear to sit much closer to the action, potentially detecting threats within the skull itself before signals ever reach those distant nodes.
"The skull bone marrow is far more than just a structural framework — it harbors previously unrecognized hubs for brain-specific immune responses."
— Jonathan Kipnis, senior author, Washington University School of Medicine
"We have never seen such structures in healthy bone marrow before. It is an exciting discovery that points out that a complex brain requires its own specialized immune structures to defend it."
— Jang Hyun Park, first author, Washington University School of Medicine
To test whether the hubs could be exploited therapeutically, the researchers built a gel combining three immune-stimulating proteins and applied it directly beneath the scalp of tumor-bearing mice. The treatment triggered a surge of antibody production within the skull marrow and an increase in immune activity directed at the tumors, according to the university's summary of the study.
The authors caution that the work so far is confined to mice and to glioblastoma, one of the deadliest and most treatment-resistant brain cancers, and that any human application remains years away. Still, they say the discovery opens a new avenue for reaching the brain's immune defenses without crossing the blood-brain barrier, and the group is now investigating whether strengthening these hubs could also help in Alzheimer's disease, Parkinson's disease and long COVID, all of which involve immune activity in or near the brain.
